A systematic review of health‐related quality of life in longitudinal studies of myeloma patients

Nielsen, Lene Kongsgaard; Jarden, Mary; Andersen, Christen Lykkegaard; Frederiksen, Henrik; Abildgaard, Niels

doi:10.1111/ejh.12882

Cited by 61 publications

(58 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty‐three longitudinal HRQoL datasets were identified for data extraction. The PRISMA flow diagram for the study selection and subdivision of publications into five treatment categories are presented in Nielsen et al (). The longitudinal PRO data from MM‐015 studies were divided into two treatment categories: first line treatment without autologous stem cell transplantation and maintenance therapy, respectively, because the HRQoL data from those two treatments could be extracted separately from the studies (Dimopoulos et al , , ).…”

Section: Resultsmentioning

confidence: 99%

“…An important aspect of the generalisability of PRO data results is that most PRO data deviates from patients included in clinical trials. This is also the case for patients with MM because 22 of the 23 studies in the systematic review are clinical trials (Nielsen et al, 2017). Newly diagnosed patients with MM included in clinical trials are not representative for the general MM population and PRO data from clinical trials might not be generally applicable (Klausen et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Methodological aspects of health‐related quality of life measurement and analysis in patients with multiple myeloma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary Multiple myeloma (MM) is an incurable but treatment‐sensitive cancer. For most patients, this means treatment with multiple lines of anti‐myeloma therapy and a life with disease‐ and treatment‐related symptoms and complications. Health‐related quality of life (HRQoL) issues play an important role in treatment decision‐making. Methodological challenges in longitudinal HRQoL measurements and analyses have been identified, including non‐responses (NR) to scheduled questionnaires. Publications were identified for inclusion in a systematic review of longitudinal HRQoL studies in MM, focussing on methodological aspects of HRQoL measurement and analysis. Diversity in timing of HRQoL data collection and applied statistical methods were noted. We observed a high rate of NR, but the impact of NR was investigated in only 8/23 studies. Thus, evidence‐based knowledge of HRQoL in patients with MM is compromised. To improve quality of HRQoL results and their implementation in daily practice, future studies should follow established guidelines.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Methodological aspects of health‐related quality of life measurement and analysis in patients with multiple myeloma

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patient survey data showed that the disease and treatment burden of NDMM were associated with productivity losses on a personal level post‐ASCT, and highlighted that losses were largely due to patients retiring or not returning to full‐time work. The economic model estimated considerable productivity losses following a diagnosis with MM and subsequent ASCT; however, data indicating maintenance therapy may improve patient HRQoL suggests social benefits beyond the economic benefits revealed in the model …”

Section: Discussionmentioning

confidence: 99%

Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy

Jackson

Galinsky

Alderson

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

Objective This study examined productivity losses in European patients with newly diagnosed multiple myeloma (NDMM) undergoing autologous stem cell transplantation (ASCT), to better understand and model the impact of NDMM and lenalidomide maintenance therapy on productivity from a patient and societal perspective. Methods A cross‐sectional online patient survey was conducted across the UK, Germany, France, Spain and Italy. A partitioned survival model was used to estimate productivity loss and the impact of maintenance therapy, using human capital (HC) and friction cost approaches. Results Of the 115 eligible survey respondents, 76.5% were economically active at the time of diagnosis and highlighted return to work as an important factor affecting their quality of life; only 39.1% of respondents were economically active post‐ASCT. HC analyses estimated average total productivity losses per ASCT patient at EUR 290,601 over a 20‐year period. Modelling the impact of maintenance therapy alone for these patients reduced average productivity losses by just over 10%. Conclusion Patients with NDMM aspire to engage in productive lives post‐ASCT, but most are unable to do so. Access to treatments extending remission and supporting engagement in a productive life can have a positive impact both for patients and wider society.

show abstract

“…2 Nevertheless, the impact on HRQoL of maintenance treatment for patients with MM is not well understood. 11,12 Ixazomib is an oral proteasome inhibitor currently indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. The phase 3 placebo-controlled, double-blind TOURMALINE-MM3 study investigated ixazomib as a MT following ASCT in adult patients newly diagnosed with MM.…”

Section: Introductionmentioning

confidence: 99%

Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial

Schjesvold

Goldschmidt

Maisnar

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Objectives:Health-related quality of life (HRQoL) is particularly important during maintenance therapy (MT) in newly diagnosed multiple myeloma post-transplant, when disease symptoms are limited. Methods:We assessed HRQoL in patients randomised to 26 cycles of MT (ixazomib vs placebo) in TOURMALINE-MM3 (NCT02181413). Results:The characteristics at study entry were well-balanced between ixazomib (n = 386) and placebo (n = 251) arms. At study entry, EORTC QLQ-C30 and MY20 scores were high for functional scales and low for symptom scales and were comparable with those of the general population. Changes in subscale scores across intervals, analysed over 30 four-week intervals using a linear mixed-effects model, were generally small and similar between arms for the EORTC QLQ-C30 Global Health Status/QoL, Physical Functioning, and Pain subscales and EORTC QLQ-MY20This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

A systematic review of health‐related quality of life in longitudinal studies of myeloma patients

Cited by 61 publications

References 64 publications

Methodological aspects of health‐related quality of life measurement and analysis in patients with multiple myeloma

Methodological aspects of health‐related quality of life measurement and analysis in patients with multiple myeloma

Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy

Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial

Contact Info

Product

Resources

About